<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03804359</url>
  </required_header>
  <id_info>
    <org_study_id>17-APN-01</org_study_id>
    <nct_id>NCT03804359</nct_id>
  </id_info>
  <brief_title>Personalized Medicine for Membranous Nephropathy</brief_title>
  <acronym>PMMN</acronym>
  <official_title>Personalized Medicine for Membranous Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, open label, multicentre (20 sites), prospective trial comparing the efficacy of&#xD;
      two therapeutic strategies to obtain clinical remission 1 year after diagnosis of Idiopathic&#xD;
      Membranous Nephropathy with nephrotic syndrome and anti-PLA2R1 (phospholipase A2 receptor 1)&#xD;
      antibodies:&#xD;
&#xD;
        -  GEMRITUX protocol: 6 months of symptomatic antihypertensive and antiproteinuric therapy,&#xD;
           and if the nephrotic syndrome persists at month-6 (urinary protein/creatinine ratio&#xD;
           (UPCR) remains &gt; 3.5 g/g and albuminemia &lt; 30 g/l), two 375 mg/m2 rituximab infusions at&#xD;
           1-week interval.&#xD;
&#xD;
        -  Personalized treatment:&#xD;
&#xD;
             -  restricted anti-CysR activity at inclusion : 6-month symptomatic antihypertensive&#xD;
                and antiproteinuric treatment (KDIGO)&#xD;
&#xD;
             -  restricted anti-CysR activity after 6 months of symptomatic treatment with&#xD;
                persisting nephrotic syndrome (UPCR remains &gt; 3.5 g/g and albuminemia &lt; 30 g/l):&#xD;
                two 375 mg/m2 rituximab infusions at 1-week interval;&#xD;
&#xD;
             -  Anti-CTLD (C-type lectin domains ) 1/7 activity at inclusion or after 6 months with&#xD;
                persisting nephrotic syndrome (UPCR remains &gt; 3.5 g/g and albuminemia &lt; 30 g/l):&#xD;
                two 1g rituximab infusions at 2-week interval at month 0 and/or month 6.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">January 14, 2020</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical remission will be defined as a composite criterion combining (KDIGO definitions)</measure>
    <time_frame>6 months</time_frame>
    <description>Complete clinical remission: urinary protein/creatinine ratio (UPCR)&lt;0.3 g/g in spot morning urine samples and serum albumin &gt; 35 g/L and eGFR (epidermal growth factor receptor) &gt; 60 ml/min/1.73 m2&#xD;
Partial clinical remission: UPCR &lt; 3.5 g/g with a decrease greater than 50% from baseline and serum albumin &gt; 30 g/L and increase of serum creatinine lower than 20%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunological remission</measure>
    <time_frame>6 months</time_frame>
    <description>full PLA2R1 depletion measured by ELISA (titer&lt;14RU (relative units) /ml)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Idiopathic Membranous Nephropathy</condition>
  <arm_group>
    <arm_group_label>GEMRITUX protocol</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>6 months of symptomatic antihypertensive and antiproteinuric therapy, and if the nephrotic syndrome persists at month-6 (urinary protein/creatinine ratio (UPCR) remains &gt; 3.5 g/g and albuminemia &lt; 30 g/l), two 375 mg/m2 rituximab infusions at 1-week interval.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Personalized treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>restricted anti-CysR activity at inclusion : 6-month symptomatic antihypertensive and antiproteinuric treatment (KDIGO)&#xD;
restricted anti-CysR activity after 6 months of symptomatic treatment with persisting nephrotic syndrome (UPCR remains &gt; 3.5 g/g and albuminemia &lt; 30 g/l): two 375 mg/m2 rituximab infusions at 1-week interval;&#xD;
Anti-CTLD1/7 activity at inclusion or after 6 months with persisting nephrotic syndrome (UPCR remains &gt; 3.5 g/g and albuminemia &lt; 30 g/l): two 1g rituximab infusions at 2-week interval at month 0 and/or month 6.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>In the &quot;personalized arm&quot;, the patient will be treated in function of the CysR activity result during the inclusion visit.</description>
    <arm_group_label>Personalized treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 years or more&#xD;
&#xD;
          -  Anti-PLA2R1 activity detected by ELISA or Euroimmune Immunofluorescence Assay&#xD;
&#xD;
          -  Nephrotic syndrome defined by proteinuria &gt; 3.5 g/24h (or UPCR &gt; 3.5 g/g) and serum&#xD;
             albumin &lt; 30 g/L at diagnosis&#xD;
&#xD;
          -  eGFR (CKD-EPI) &gt; 30 ml/min/1,73 m2 at diagnosis&#xD;
&#xD;
          -  Symptomatic treatment according to KDIGO guidelines: maximal tolerated dose of NIAT :&#xD;
             Non Immunosuppressive Antiproteinuric Treatment (angiotensin-converting enzyme&#xD;
             inhibitor and/or angiotensin 2 receptor blockers, diuretics and statins)&#xD;
&#xD;
          -  Medical insurance&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Having understood and accepted the need for long-term medical follow-up&#xD;
&#xD;
          -  Woman of child-bearing age must be using an effective method of contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Secondary Membranous Nephropathy: Membranous Nephropathy related to cancer,&#xD;
             infectious, systemic lupus erythematosis, drug&#xD;
&#xD;
          -  Anti-PLA2R1 antibodies not confirmed by central analysis (in this case the patient&#xD;
             will be replaced)&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Immunosuppressive treatment in the 3 last months&#xD;
&#xD;
          -  Cancer under treatment&#xD;
&#xD;
          -  Patient with complicated nephrotic syndrome that would require early immunosuppressive&#xD;
             treatment (thrombosis, acute renal failure…)&#xD;
&#xD;
          -  Patients with active, severe infections or active hepatitis B&#xD;
&#xD;
          -  Hypersensitivity to the active substance or to murine proteins, or to any of the other&#xD;
             excipients&#xD;
&#xD;
          -  Patients in a severely immunocompromised state&#xD;
&#xD;
          -  Severe heart failure (New York Heart Association Class IV) or severe, uncontrolled&#xD;
             cardiac disease&#xD;
&#xD;
          -  Patients unable to give an informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara SEITZ-POLSKI</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Nice</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Barbara SEITZ-POLSKI, MD</last_name>
    <phone>04 92 03 55 02</phone>
    <email>seitz-polski.b@chu-nice.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Céline FERNANDEZ</last_name>
    <email>fernandez.c3@chu-nice.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU D'amiens Hôpital Sud</name>
      <address>
        <city>Amiens</city>
        <zip>80800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gabriel CHOUKROUN</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Besançon</name>
      <address>
        <city>Besançon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Céline COURNIVAUD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital universitaire La Cavale Blanche</name>
      <address>
        <city>Brest</city>
        <zip>29069</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emilie CORNEC-LE GALL</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Caen</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antoine LANOT</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Gabriel Montpied</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne-Elisabeth HENG</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vincent AUDARD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de LILLE</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Céline LEBAS</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de LYON NORD</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fitsum GUEBRE-EGZIABHER</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AP-HM</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Noémie JOURDE-CHICHE</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Moglie LE QUINTREC</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de NANTES</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fadi FAKHOURI</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dr Barbara SEITZ-POLSKI</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara SEITZ-POLSKI, MD</last_name>
      <phone>04 92 03 55 02</phone>
      <email>seitz-polski.b@chu-nice.fr</email>
    </contact>
    <contact_backup>
      <last_name>Céline FERNANDEZ</last_name>
      <phone>04 92 03 88 28</phone>
      <email>fernandez.c3@chu-nice.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Vincent ESNAULT, MD; PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Carémeau</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier MORANNE</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Necker</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bertrand KNEBELMANN</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Le Kremlin Bicêtre</name>
      <address>
        <city>Paris</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antoine DURRBACH</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital de la maison blanche</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philippe RIEU</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thierry KRUMMEL</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dominique CHAUVEAU</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Michel HALIMI</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Simon N, Courouce AM, Lemarrec N, Trepo C, Ducamp S. A twelve year natural history of hepatitis C virus infection in hemodialyzed patients. Kidney Int. 1994 Aug;46(2):504-11. doi: 10.1038/ki.1994.301.</citation>
    <PMID>7967364</PMID>
  </reference>
  <reference>
    <citation>Simon P, Ramee MP, Boulahrouz R, Stanescu C, Charasse C, Ang KS, Leonetti F, Cam G, Laruelle E, Autuly V, Rioux N. Epidemiologic data of primary glomerular diseases in western France. Kidney Int. 2004 Sep;66(3):905-8. doi: 10.1111/j.1523-1755.2004.00834.x.</citation>
    <PMID>15327379</PMID>
  </reference>
  <reference>
    <citation>Ponticelli C. Membranous nephropathy. J Nephrol. 2007 May-Jun;20(3):268-87.</citation>
    <PMID>17557260</PMID>
  </reference>
  <reference>
    <citation>Glassock RJ. The pathogenesis of idiopathic membranous nephropathy: a 50-year odyssey. Am J Kidney Dis. 2010 Jul;56(1):157-67. doi: 10.1053/j.ajkd.2010.01.008. Epub 2010 Apr 8.</citation>
    <PMID>20378220</PMID>
  </reference>
  <results_reference>
    <citation>Lassalle M, Ayav C, Frimat L, Jacquelinet C, Couchoud C; Au Nom du Registre REIN. The essential of 2012 results from the French Renal Epidemiology and Information Network (REIN) ESRD registry. Nephrol Ther. 2015 Apr;11(2):78-87. doi: 10.1016/j.nephro.2014.08.002. Epub 2014 Nov 1.</citation>
    <PMID>25457107</PMID>
  </results_reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 11, 2019</study_first_submitted>
  <study_first_submitted_qc>January 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 15, 2019</study_first_posted>
  <last_update_submitted>February 7, 2020</last_update_submitted>
  <last_update_submitted_qc>February 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nephrotic Syndrome</keyword>
  <keyword>PLA2R1-antibodies</keyword>
  <keyword>Epitope spreading</keyword>
  <keyword>Rituximab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Glomerulonephritis, Membranous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03804359
org study id: 17-APN-01
nct id: NCT03804359
lead sponsor: 
has dmc: No
is fda regulated drug: No
is fda regulated device: No
Randomized, open label, multicentre (20 sites), prospective trial comparing the efficacy of
      two therapeutic strategies to obtain clinical remission 1 year after diagnosis of Idiopathic
      Membranous Nephropathy with nephrotic syndrome and anti-PLA2R1 (phospholipase A2 receptor 1)
      antibodies:

        -  GEMRITUX protocol: 6 months of symptomatic antihypertensive and antiproteinuric therapy,
           and if the nephrotic syndrome persists at month-6 (urinary protein/creatinine ratio
           (UPCR) remains > 3.5 g/g and albuminemia < 30 g/l), two 375 mg/m2 rituximab infusions at
           1-week interval.

        -  Personalized treatment:

             -  restricted anti-CysR activity at inclusion : 6-month symptomatic antihypertensive
                and antiproteinuric treatment (KDIGO)

             -  restricted anti-CysR activity after 6 months of symptomatic treatment with
                persisting nephrotic syndrome (UPCR remains > 3.5 g/g and albuminemia < 30 g/l):
                two 375 mg/m2 rituximab infusions at 1-week interval;

             -  Anti-CTLD (C-type lectin domains ) 1/7 activity at inclusion or after 6 months with
                persisting nephrotic syndrome (UPCR remains > 3.5 g/g and albuminemia < 30 g/l):
                two 1g rituximab infusions at 2-week interval at month 0 and/or month 6.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: Clinical remission will be defined as a composite criterion combining (KDIGO definitions)
time frame: 6 months
description: Complete clinical remission: urinary protein/creatinine ratio (UPCR)<0.3 g/g in spot morning urine samples and serum albumin > 35 g/L and eGFR (epidermal growth factor receptor) > 60 ml/min/1.73 m2
Partial clinical remission: UPCR < 3.5 g/g with a decrease greater than 50% from baseline and serum albumin > 30 g/L and increase of serum creatinine lower than 20%
measure: Immunological remission
time frame: 6 months
description: full PLA2R1 depletion measured by ELISA (titer<14RU (relative units) /ml)
arm group label: GEMRITUX protocol
arm group type: No Intervention
description: 6 months of symptomatic antihypertensive and antiproteinuric therapy, and if the nephrotic syndrome persists at month-6 (urinary protein/creatinine ratio (UPCR) remains > 3.5 g/g and albuminemia < 30 g/l), two 375 mg/m2 rituximab infusions at 1-week interval.
arm group label: Personalized treatment
arm group type: Experimental
description: restricted anti-CysR activity at inclusion : 6-month symptomatic antihypertensive and antiproteinuric treatment (KDIGO)
restricted anti-CysR activity after 6 months of symptomatic treatment with persisting nephrotic syndrome (UPCR remains > 3.5 g/g and albuminemia < 30 g/l): two 375 mg/m2 rituximab infusions at 1-week interval;
Anti-CTLD1/7 activity at inclusion or after 6 months with persisting nephrotic syndrome (UPCR remains > 3.5 g/g and albuminemia < 30 g/l): two 1g rituximab infusions at 2-week interval at month 0 and/or month 6.
intervention type: Drug
intervention name: Rituximab
description: In the "personalized arm", the patient will be treated in function of the CysR activity result during the inclusion visit.
arm group label: Personalized treatment
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Barbara SEITZ-POLSKI
role: Principal Investigator
affiliation: Centre Hospitalier Universitaire de Nice
last name: Barbara SEITZ-POLSKI, MD
phone: 04 92 03 55 02
email: seitz-polski.b@chu-nice.fr
last name: Céline FERNANDEZ
email: fernandez.c3@chu-nice.fr
facility: 
status: Not yet recruiting
contact: 
facility: 
status: Not yet recruiting
contact: 
facility: 
status: Not yet recruiting
contact: 
facility: 
status: Not yet recruiting
contact: 
facility: 
status: Not yet recruiting
contact: 
facility: 
status: Not yet recruiting
contact: 
facility: 
status: Not yet recruiting
contact: 
facility: 
status: Not yet recruiting
contact: 
facility: 
status: Not yet recruiting
contact: 
facility: 
status: Not yet recruiting
contact: 
facility: 
status: Not yet recruiting
contact: 
facility: 
status: Recruiting
contact: 
contact backup: 
investigator: 
facility: 
status: Recruiting
contact: 
facility: 
status: Not yet recruiting
contact: 
facility: 
status: Not yet recruiting
contact: 
facility: 
status: Not yet recruiting
contact: 
facility: 
status: Not yet recruiting
contact: 
facility: 
status: Not yet recruiting
contact: 
facility: 
status: Not yet recruiting
contact: 
country: France
citation: Simon N, Courouce AM, Lemarrec N, Trepo C, Ducamp S. A twelve year natural history of hepatitis C virus infection in hemodialyzed patients. Kidney Int. 1994 Aug;46(2):504-11. doi: 10.1038/ki.1994.301.
PMID: 7967364
citation: Simon P, Ramee MP, Boulahrouz R, Stanescu C, Charasse C, Ang KS, Leonetti F, Cam G, Laruelle E, Autuly V, Rioux N. Epidemiologic data of primary glomerular diseases in western France. Kidney Int. 2004 Sep;66(3):905-8. doi: 10.1111/j.1523-1755.2004.00834.x.
PMID: 15327379
citation: Ponticelli C. Membranous nephropathy. J Nephrol. 2007 May-Jun;20(3):268-87.
PMID: 17557260
citation: Glassock RJ. The pathogenesis of idiopathic membranous nephropathy: a 50-year odyssey. Am J Kidney Dis. 2010 Jul;56(1):157-67. doi: 10.1053/j.ajkd.2010.01.008. Epub 2010 Apr 8.
PMID: 20378220
citation: Lassalle M, Ayav C, Frimat L, Jacquelinet C, Couchoud C; Au Nom du Registre REIN. The essential of 2012 results from the French Renal Epidemiology and Information Network (REIN) ESRD registry. Nephrol Ther. 2015 Apr;11(2):78-87. doi: 10.1016/j.nephro.2014.08.002. Epub 2014 Nov 1.
PMID: 25457107
responsible party type: Sponsor
mesh term: Kidney Diseases
mesh term: Glomerulonephritis, Membranous
mesh term: Rituximab